HB6255, titled the Affordable Insulin Now Act, would cap out-of-pocket costs for certain insulin products in most private health coverage. For plan years beginning on or after January 1, 2026, group health plans and health insurance issuers offering group or individual coverage would have to cover at least one selected insulin product in each dosage form and insulin type when available, with no deductible applied to those products and cost-sharing limited to the lesser of $35 per 30-day supply or 25% of the negotiated price net of price concessions. The bill applies this framework across the Public Health Service Act, the Internal Revenue Code, and ERISA so that the same basic insulin cost-sharing rules would govern fully insured plans, employer-sponsored plans, and related tax code provisions.
The bill also clarifies that these insulin cost-sharing limits count toward deductibles and out-of-pocket maximums, and it extends the requirement to catastrophic plans under the Affordable Care Act so that selected insulin products must be covered before an enrollee reaches the annual cost-sharing limit. At the same time, it preserves plan flexibility by allowing higher cost-sharing for out-of-network insulin and by not requiring coverage of insulin products that are not selected insulin products, if otherwise permitted by law. The bill further states that the deductible exemption for selected insulin products should not affect actuarial value calculations for qualified health plans.
Impact
If enacted, HB6255 would amend federal health coverage law, the Internal Revenue Code, ERISA, and ACA market rules to create a uniform federal insulin affordability standard. It would directly affect group health plans, health insurance issuers, employer-sponsored coverage, and catastrophic plans, while also limiting how insurers and plans can structure cost-sharing for covered insulin products. The bill would not broadly regulate all diabetes medications, only selected insulin products as defined in the legislation, and it would leave room for out-of-network cost-sharing and for higher cost-sharing on non-selected insulin products.
Sentiment
The available context suggests the bill is intended as a consumer-protection and affordability measure, with a clear pro-patient orientation centered on lowering insulin costs for people with diabetes. No committee transcripts or recorded votes were provided, so there is no documented opposition or amendment debate in the supplied materials. Based on the text alone, the bill appears designed to address a widely recognized affordability problem and would likely be viewed favorably by patient advocates and many health care stakeholders focused on prescription drug access.
Contention
The main policy tensions in the bill are likely to involve cost and coverage design. Insurers and employer plan sponsors may object to the mandated deductible waiver and the $35-or-25%-of-negotiated-price cap because it constrains benefit design and may shift costs elsewhere. Another possible point of contention is the bill’s use of “selected insulin products,” which gives plans some discretion over which insulin products are covered under the cap, potentially raising concerns about formulary limitations or uneven access. The bill also preserves higher out-of-network cost-sharing, which may be acceptable to insurers but could be criticized by patients who need non-network care.